-
Mashup Score: 7Other Specialties - 4 month(s) ago
Beyond our core therapeutic areas, our researchers study a diverse set of diseases with high unmet needs where we believe great progress for patients is possible. Our teams are advancing the research and development for diseases that share one commonality — we believe that innovation will lead to new discoveries. Areas of interest include Hepatitis C, HIV, COVID-19, pulmonology, endocrinology, gastrointestinal diseases, and therapeutic neurotoxins. Our scientific talent and experience are as diverse as
Source: www.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Point-of-diagnosis HCV treatment model yields 95% SVR at 12 weeks among marginalized group - 5 month(s) ago
A test-and-treat model for hepatitis C virus infection among injection drug users and people experiencing homelessness resulted in high levels of treatment initiation, completion and cure, and may expand care access to marginalized groups. “Marginalized populations, including people experiencing homelessness or housing instability, people in marginalized racial and ethnic groups, people
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
According to data 📈 from @JAMANetworkOpen: A test-and-treat model for #HCV among injection drug users, people experiencing homelessness resulted in high levels of treatment initiation, completion and cure. Learn more at the 🔗below👇🏼 https://t.co/0o7WLsum6p
-
-
Mashup Score: 1Point-of-diagnosis HCV treatment model yields 95% SVR at 12 weeks among marginalized group - 5 month(s) ago
A test-and-treat model for hepatitis C virus infection among injection drug users and people experiencing homelessness resulted in high levels of treatment initiation, completion and cure, and may expand care access to marginalized groups. “Marginalized populations, including people experiencing homelessness or housing instability, people in marginalized racial and ethnic groups, people
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
According to data 📈 from @JAMANetworkOpen: A test-and-treat model for #HCV among injection drug users, people experiencing homelessness resulted in high levels of treatment initiation, completion and cure. Learn more at the 🔗below👇🏼 https://t.co/0o7WLsum6p
-
-
Mashup Score: 0Point-of-diagnosis HCV treatment model yields 95% SVR at 12 weeks among marginalized group - 5 month(s) ago
A test-and-treat model for hepatitis C virus infection among injection drug users and people experiencing homelessness resulted in high levels of treatment initiation, completion and cure, and may expand care access to marginalized groups. “Marginalized populations, including people experiencing homelessness or housing instability, people in marginalized racial and ethnic groups, people
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
According to data 📈 from @JAMANetworkOpen: A test-and-treat model for #HCV among injection drug users, people experiencing homelessness resulted in high levels of treatment initiation, completion and cure. Learn more at the 🔗below👇🏼 https://t.co/0o7WLsum6p
-
-
Mashup Score: 1
The seroprevalence of HCV antibody among pregnant women was significantly greater among those with opioid use disorder and HIV infection, as well as in lower-middle-income countries and those with low levels of HDI.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Findings from a systematic review and meta-analysis show pregnant women face a high burden of exposure to #HCV, especially among those with opioid use disorder and HIV infection. https://t.co/CiIbJJPPAh https://t.co/qm43fjTpKK
-
-
Mashup Score: 0
8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Results from the multicenter EpiTer-2 project showed an 8-week glecaprevir/pibrentasvir regimen is safe and effective for the treatment of #HCV in children. Learn more: https://t.co/TX5H89dZJb https://t.co/97vpXEo4GM
-
-
Mashup Score: 0New Model Uses Longitudinal Data to Predict HCC Risk in Patients with HCV-Related Cirrhosis - 5 month(s) ago
The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A longitudinal model for predicting HCC risk after SVR in patients with #HCV-related cirrhosis is highlighting the importance of using repeated measurements of predictor variables rather than just those obtained at baseline. Learn more: https://t.co/r2Z24rhCzR https://t.co/ltumDhQsiU
-
-
Mashup Score: 0Glecaprevir/Pibrentasvir Therapy Effectively Treats Acute Hepatitis C Virus Infection - 5 month(s) ago
Therapy with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at posttreatment week 12 rate, which was superior to the prior efficacy threshold.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Therapy with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at posttreatment week 12 rate, which was superior to the prior efficacy threshold. https://t.co/f7q9TAFzI9 #HCV
-
-
Mashup Score: 0Updates on HCV Screening, Access to Treatment, and Prevention - 7 month(s) ago
Thought leaders examine challenges and opportunities in HCV screening and prevention, in highlights from a recent State of the Science SummitTM, presented by HCP Live®
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Explore strategies for #HCV prevention by expanding access to treatment. Watch the Updates on HCV Screening, Access to Treatment, and Prevention on-demand workshop. #infectiousdiseases https://t.co/8mbLA2aQGK https://t.co/TZ5MkDRTV1
-
An exclusive event from our partners at HCPLive®. Explore strategies for #HCV prevention by expanding access to treatment. Watch the Updates on HCV Screening, Access to Treatment, and Prevention on-demand workshop. #infectiousdiseases https://t.co/68PUZn1Dy4 https://t.co/PELVd1UZOG
-
-
Mashup Score: 0
Results showed a significant improvement in patient-reported physical well-being after 12 weeks of treatment with sofosbuvir/velpatasvir.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Self-reported physical well-being significantly improved after 12 weeks of treatment with sofosbuvir/velpatasvir, highlighting its impact on health-related quality of life in children with #HCV Learn more: https://t.co/RKj6Kpax1k https://t.co/6bgOVL1Jie
-
80% of people infected with hepatitis C virus (HCV) may not initially show symptoms. With early diagnosis, timely testing and treatment, #HCV elimination is possible. Learn more about our work to support global elimination efforts: https://t.co/K5Ueb3pq4T https://t.co/TbbptInlkA